Compare Charles River Laboratories Intl. Inc (CRL) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Schwab US Dividend Equity ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $285.91 (market cap $13.46B), while Schwab US Dividend Equity ETF trades at $34.17. Which is the better fit depends on your goals.
| CRL | SCHD | |
|---|---|---|
Market Cap | $13.46B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $282.00 | $34.27 |
52-Week Low | $145.57 | $26.44 |
Enterprise Value | $16.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
SCHD trades at $34.11, down 0.23% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF is a core holding for dividend investors, highlighted by a recent $0.25 dividend declaration for June 2026. Media coverage emphasizes its role in retirement income strategies, though some articles note performance gaps versus peers like VYM.
Outlook remains stable for income-focused investors, with SCHD offering reliable dividends amid market rotations. Risks include interest rate sensitivity and tax inefficiencies in taxable accounts. Institutional interest persists, as seen in Barry Investment Advisors' 29.9% stake increase in Q2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
